Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow Reinvestment Rate
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Reinvestment Rate of 0.64x as of March 2026, reinvesting $31.92 Million (capex $161.00K plus investments $-31.75 Million) from operating cash flow of $50.20 Million. Explore Kiniksa Pharmaceuticals Ltd (KNSA) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Kiniksa Pharmaceuticals Ltd Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for Kiniksa Pharmaceuticals Ltd across 4 annual periods. Also explore KNSA asset base for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Kiniksa Pharmaceuticals Ltd (2022–2025)
Year-by-year capital reinvestment analysis for Kiniksa Pharmaceuticals Ltd. For live market cap and broader valuation context, see market cap of Kiniksa Pharmaceuticals Ltd.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 7.31x | $187.70 Million | $25.69 Million | $277.00K | ▲ +394.6% |
| 2024 | 1.48x | $37.95 Million | $25.69 Million | $277.00K | ▼ -65.8% |
| 2023 | 4.32x | $57.45 Million | $13.30 Million | $130.00K | ▲ +207.1% |
| 2022 | 1.41x | $8.17 Million | $5.81 Million | $105.00K | — |